Texas Biomed files patent for a novel HIV vaccine strategy

November 19, 2012

The Texas Biomedical Research Institute in San Antonio has applied for a patent for a genetically-engineered vaccine strategy to prevent HIV infection that targets the outer layers of body structures that are the first sites of contact with the virus.

Designed to be a single dose and last a lifetime, the vaccine will lead to the continual production of disease-fighting cells without being eliminated by the immune system. Another feature of the vaccine system is that it could be adapted for use against other infections.

More than 90 percent of new HIV infections worldwide are transmitted by through outer layers of cells called epithelial cells which line the surfaces of structures throughout the body. The new vaccine is directed to what are known as the mucosal layers of the epithelium in the genital and rectal areas where the virus enters the body.

"The development of an effective that restricts at the mucosal level of entry may be our best hope for controlling the HIV pandemic," said Marie-Claire Gauduin, Ph.D., of Texas Biomed's Department of Virology and Immunology, who is a co-inventor on the patent with Philippe Blancou, Ph.D., a visiting scientist from the University of Nice-Sophia Antipolis, France. "Only life-long stimulation of the immune system by the vaccine will be sufficient to achieve long-term protection," she added.

One of the main reasons for the failure of HIV vaccines thus far is their inability to deliver antibody-producing cells for prolonged periods of time, thus only achieving weak and transient protection at best.

The primary target for through different mucosal sites varies depending on the tissue. However, soon after crossing the mucosal layer, HIV rapidly spreads to lymph nodes and other organs where it replicates.

The will have a molecule and stem cell gene tagged to target epithelial cells, that combined, will promote the production of antibody-producing cells. Thus, the epithelial layer will continuously release new antibody-producing cells and not be eliminated by the body's immune response.

Explore further: Penile foreskin is immunologically complete: raises new vaccine possibilities for HIV vaccine

Related Stories

Recommended for you

Researchers use CRISPR to accelerate search for HIV cure

October 25, 2016

Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.

Study unlocks secret of common HIV strain

October 13, 2016

A discovery that the most common variant of the HIV virus is also the "wimpiest" will help doctors better treat millions of individuals around the world suffering from the deadly disease, according to one of the world's leading ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.